Beijing Hotgen Biotech Co Ltd - Asset Resilience Ratio
Beijing Hotgen Biotech Co Ltd (688068) has an Asset Resilience Ratio of 20.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 688068 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Beijing Hotgen Biotech Co Ltd's Asset Resilience Ratio has changed over time. See 688068 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Beijing Hotgen Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688068 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥669.32 Million | 20.87% |
| Total Liquid Assets | CN¥669.32 Million | 20.87% |
Asset Resilience Insights
- Good Liquidity Position: Beijing Hotgen Biotech Co Ltd maintains a healthy 20.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Beijing Hotgen Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Hotgen Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Beijing Hotgen Biotech Co Ltd (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Hotgen Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.06% | CN¥201.51 Million ≈ $29.49 Million |
CN¥3.33 Billion ≈ $486.68 Million |
-1.81pp |
| 2023-12-31 | 7.86% | CN¥280.02 Million ≈ $40.98 Million |
CN¥3.56 Billion ≈ $521.03 Million |
-14.93pp |
| 2022-12-31 | 22.79% | CN¥888.68 Million ≈ $130.04 Million |
CN¥3.90 Billion ≈ $570.59 Million |
-2.65pp |
| 2021-12-31 | 25.45% | CN¥927.45 Million ≈ $135.71 Million |
CN¥3.64 Billion ≈ $533.36 Million |
-- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more